cyproheptadine/prazosin (KT-110) / Kinnov Therap - LARVOL DELTA

A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Kinnov Therapeutics | Not yet recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Jul 2024

Trial completion • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)

A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Kinnov Therapeutics

Trial completion date • Trial initiation date • Trial primary completion date • Addiction (Opioid and Alcohol)

A Phase 1 Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Kinnov Therapeutics

New P1 trial • Addiction (Opioid and Alcohol)

COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - P2 | N=154 | Completed | Sponsor: Kinnov Therapeutics | Active, not recruiting ➔ Completed

Adverse events • Clinical data • Trial completion • Addiction (Opioid and Alcohol)

COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - P2; N=154; Active, not recruiting; Sponsor: Kinnov Therapeutics; Recruiting ➔ Active, not recruiting

Adverse events • Clinical • Clinical data • Enrollment closed • Addiction (Opioid and Alcohol)

COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - P2; N=180; Recruiting; Sponsor: Kinnov Therapeutics; Trial completion date: May 2021 ➔ Jan 2022; Trial primary completion date: Feb 2021 ➔ Oct 2021

Adverse events • Clinical • Clinical data • Trial completion date • Trial primary completion date

COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - P2; N=180; Recruiting; Sponsor: Kinnov Therapeutics; Not yet recruiting ➔ Recruiting

Adverse events • Clinical • Clinical data • Enrollment open

COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - P2; N=180; Not yet recruiting; Sponsor: Kinnov Therapeutics

Adverse events • Clinical • Clinical data • New P2 trial